# Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF

Study · id `cardio:ct-nct04198701` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04198701](<https://clinicaltrials.gov/study/NCT04198701>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04198701

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 421 participants.

## Technical summary

Registry record NCT04198701. Non-randomized; no masking; primary purpose treatment. Start 2019-12-10 (actual); primary completion 2022-11-28 (actual). Results posted on 2023-12-13.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 421 participants (enrolled count; ClinicalTrials.gov record NCT04198701, source copy `cardio:ctgov-nct04198701-2025-02-13`, retrieved 2026-10-26)
- Started: 2019-12-10 (actual) (ClinicalTrials.gov record NCT04198701, source copy `cardio:ctgov-nct04198701-2025-02-13`, retrieved 2026-10-26)
- Primary completion: 2022-11-28 (actual) (ClinicalTrials.gov record NCT04198701, source copy `cardio:ctgov-nct04198701-2025-02-13`, retrieved 2026-10-26)
- Completion: 2022-11-28 (actual) (ClinicalTrials.gov record NCT04198701, source copy `cardio:ctgov-nct04198701-2025-02-13`, retrieved 2026-10-26)
- Results first posted: 2023-12-13 (ClinicalTrials.gov record NCT04198701, source copy `cardio:ctgov-nct04198701-2025-02-13`, retrieved 2026-10-26)
- Countries: United States; Australia; Austria; Belgium; Canada; France; Japan; Netherlands; Spain (ClinicalTrials.gov record NCT04198701, source copy `cardio:ctgov-nct04198701-2025-02-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04198701-2025-02-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF
- Acronym: PULSED AF
- Condition: Atrial Fibrillation
- Intervention (Device): Medtronic PulseSelect Pulsed Field Ablation (PFA) System
- Lead sponsor: Medtronic Cardiac Ablation Solutions
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Medtronic Cardiac Ablation Solutions (`cardio:org-medtronic-cardiac-ablation-solutions`)

## Provenance

Content hash: ac8d1f0e9e7fa35242cb8902e12c0b134c73716c6ca6f31ddd31f0fbed5adbcf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
